Articles tagged with Breast Cancer
A study by Cancer Research UK found that teens who watch TV with adverts are more likely to eat unhealthy foods like crisps, biscuits, and fizzy drinks, consuming up to 500 extra snacks a year. The report suggests that reducing junk food TV marketing could help halt the obesity crisis.
A prospective cohort study found that young women diagnosed with breast cancer who carry a BRCA mutation have the same chances of survival as women without the mutation. After treatment, women with early breast cancer and BRCA mutations do not have a significant difference in overall survival compared to those without the mutation.
Researchers found that DNA repair-related biomarkers, including BRF1, BRCA1/2, and MPO, can predict outcomes in gastric cancer patients who abuse alcohol. These biomarkers were associated with disease recurrence, survival rates, and response to chemotherapy.
Researchers have identified MED1 as a key player in HER2-driven breast cancer development and spread. The study found that mutating MED1 disrupted its interaction with the estrogen receptor, significantly delaying tumor growth and cancer stem-like cell formation.
A study found that new treatments and screening methods have reduced breast cancer deaths by 49% since 2012, compared to 37% in 2000. The reduction is largely due to advances in treatment, with screening contributing 31-48% depending on the molecular subtype.
A recent study by USC researchers found that survival among adolescents and young adults with cancer has not improved over the past three decades. The study breaks down cancer survival rates by race, ethnicity, age group, socioeconomic status, and cancer stage, highlighting disparities in health outcomes.
University of Alberta researchers found that the RYBP protein prevents DNA repair in cancer cells, including breast cancer. This discovery could lead to precision medicine by tailoring treatment to individual patients' DNA.
Scientists developed a method to analyze lymph node tissue, identifying patients with higher risk of secondary cancers. The study found that analyzing architectural features of cancer-free lymph nodes can help differentiate between patients at high and low risk of metastasis.
A new study by Georgetown University Medical Center researchers found that a widely used gene expression profile test to predict breast cancer recurrence is less cost-effective in real-world practice. The test, Oncotype DX, was initially considered cost-effective but its accuracy and implementation in community settings make it less so.
Research from Anglia Ruskin University found that women dissatisfied with their breast size are less likely to perform regular self-examinations for breast cancer. Greater breast size dissatisfaction also leads to lower confidence in detecting changes and delayed medical consultations.
A new single-cell sequencing tool, TSCS, has provided a clearer understanding of how ductal carcinoma in situ (DCIS) progresses to invasive ductal carcinoma (IDC). Genome evolution occurs in the ducts before cancer clones can be disseminated, and most mutations evolve within the ducts prior to invasion.
The Society of Nuclear Medicine and Molecular Imaging has published appropriate use criteria (AUC) for somatostatin receptor PET imaging in neuroendocrine tumors. This AUC addresses several clinical scenarios for diagnosing neuroendocrine tumors (NETs).
The US cancer death rate has dropped 26% since its peak in 1991, resulting in nearly 2.4 million fewer cancer deaths. This decline is mainly due to reductions in smoking and advances in early detection and treatment.
A study led by The Ottawa Hospital and University of Ottawa suggests combining oncolytic viruses with checkpoint inhibitors could cure resistant breast cancer in mice. This combination therapy showed success in models that mimic metastatic spread after surgery, curing 60-90% of mice.
Researchers found that combining oncolytic viruses and checkpoint inhibitors cured 60-90% of triple negative breast cancer in mice, while traditional treatments failed. The combination therapy showed promising results, but further research is needed to test its efficacy in humans.
The NRG Oncology trial found that trastuzumab did not negatively affect cardiac function in patients with node-positive, HER2-positive breast cancer who survived without cancer recurrence. Both groups maintained good cardiac function at a median of 8.8 years after treatment.
Individualized risk-based lung cancer screening using calculators that account for demographic and clinical characteristics may save more lives than current USPSTF recommendations. Researchers estimate that this approach could have prevented over 5,000 more deaths in 2015 compared to the current guidelines.
Scientists at UTHealth and UT Health San Antonio are developing an innovative antibody-based drug to stem the spread of breast cancer to bone, linked to reduced survival rates. The goal is to create a less toxic treatment and reduce deaths tied to breast cancer's spread.
Researchers discovered a mechanism to regulate switching between breast cancer-associated genes, using G-quadruplex structures. The study provides new insights into alternative splicing and could lead to the development of novel therapeutic strategies for controlling cancer growth.
A team of researchers identified a crucial region in Numb that binds and inhibits Mdm2, stabilizing p53 levels. This interaction is key to understanding the regulation of p53 in breast cancers, which tend to retain a functional p53 gene.
A new DNA marker discovered by University College London researchers can detect fatal breast cancer up to a year before symptoms appear. The EFC#93 DNA methylation marker in blood serum correctly identified 43% of women who went on to be diagnosed with fatal breast cancer within three to six months.
Researchers at Hokkaido University have identified a cellular protein called STAP-2 that stabilizes the EGFR signaling pathway, leading to increased cell proliferation and tumor formation in prostate cancer. Suppressing STAP-2 with inhibitors could potentially treat Gefitinib-resistant prostate cancers.
Researchers have discovered that interferon-β can impair the migration and formation of tumors in triple-negative breast cancer cells, suggesting a potential new treatment option for patients. Elevated interferon-β levels in breast tissue correlate with extended patient survival and lower cancer recurrence rates.
Researchers identified mutational signatures characteristic of homologous recombination deficiency (HRD) as associated with improved clinical outcomes to platinum-based chemotherapy. High HRDetect scores were significantly linked to radiographic tumor shrinkage and longer overall survival in patients treated with the medication.
A recent study found that the majority of women with breast cancer report not feeling completely informed about their treatment options. The study suggests that patients often prioritize making a quick decision over thoroughly researching their options. To address this issue, researchers recommend providing consistent, reliable informa...
A new study found that inherited variation in the ADAMTSL1 gene is associated with a poorer survival rate in early-onset breast cancer patients. The research, published in Nature Communications, suggests that this genetic factor may be used to improve prognostic models and inform treatment decisions.
Researchers have developed an AI application that can detect lymph node metastases in breast cancer patients with high accuracy, similar to human pathologists. This breakthrough could improve the efficiency of surgical pathology work and provide better prognostication.
Researchers used digital pathology slide images to train computer algorithms that could detect the spread of breast cancer to lymph nodes with high accuracy. The study found that AI algorithms outperformed human pathologists in detecting cancer spread, suggesting potential improvements in diagnosis and treatment outcomes.
Breast cancer survivors who consumed more soy foods and cruciferous vegetables experienced fewer menopausal symptoms and fatigue. Phytochemicals in these foods may modulate inflammation and estrogen levels, potentially reducing treatment-related side effects.
A Stanford-led study of nearly 3,000 women with early stage breast cancer reveals a significant decline in chemotherapy use between 2013 and 2015, from 34.5% to 21.3%. This decrease reflects a growing trend towards personalized treatment approaches, with physicians increasingly considering tumor genomic testing to guide treatment choices.
Researchers found that low PUMA expression distinguishes stem-like cells in cancer patients who experienced tumor recurrence. Reducing PUMA restores metastasis in cultured cells, highlighting a possible Achilles heel in aggressive breast cancers.
Researchers found that SHARPIN increases PRMT5 activity, boosting transcription factors that contribute to melanoma growth. SHARPIN acts as a counterbalance to reduced PRMT5 activity in tumors with deleted genes.
A study found that younger women with breast cancer who underwent axillary lymph node dissection were more likely to experience arm swelling and decreased range of motion compared to those who received sentinel lymph node biopsies. The study highlights the importance of de-escalating axillary treatment in young patients.
A study found that 3-D mammography, although more expensive upfront, is a cost-effective screening method due to its higher true negative rates and lower false positive rates compared to digital mammography. The analysis of 46,483 screening episodes showed that DBT reduced cancer diagnosis-related costs in the following year.
A Phase III trial led by MD Anderson Cancer Center found that talazoparib, a PARP inhibitor, extends progression-free survival and improves quality-of-life measures for patients with metastatic HER2-negative breast cancer and BRCA1/2 mutations. Talazoparib was associated with a 46% lower risk of progression compared to chemotherapy.
University of Illinois researchers create an oxygen-sensitive molecular beacon that emits ultrasound signals in response to light, enabling real-time imaging of hypoxic tumors and constricted arteries. This non-invasive method has the potential to guide surgical procedures and treatment plans.
A simple blood test detecting tumor cells in blood may predict high or low risk of breast cancer relapse. The study found that 5% of cancer-free women had a positive CTC test, associated with a 35% recurrence risk after two years.
A phase II trial shows that combining olaparib, a PARP inhibitor, with durvalumab, an immunotherapy drug, achieves 80% disease control at 12 weeks. The treatment is well-tolerated and produces fewer serious side effects compared to chemotherapy.
A recent study by UNC Lineberger Comprehensive Cancer Center researchers found that black women with hormone-receptor positive, HER2-negative breast cancer had a higher risk of recurrence compared to white women. The biological features of patients' tumors partially explained this difference, but not completely.
The I-SPY 2 TRIAL found that achieving pathological complete response (pCR) is a strong predictor of event-free and distant disease-free survival in high-risk breast cancer patients. pCR rates varied by breast cancer subtype, but the relationship between pCR and EFS was significant across all subtypes.
A large-scale study reveals acupuncture to be effective in alleviating joint pain experienced by breast cancer patients undergoing hormone therapy. The treatment resulted in significant pain relief for up to 24 weeks, providing a promising alternative to opioids and other medications.
African American women face significant disparities in breast cancer care, including delayed treatment and follow-up. The TRIP project aims to reduce these disparities by integrating three evidence-based strategies into a cohesive package across six hospitals.
A study published in PLOS ONE found that metformin can prevent the development of multidrug-resistant breast cancer and reverse it after its onset. The research suggests that metformin has potential as a treatment option for aggressive breast cancer, warranting further investigation.
Researchers found that contrast-enhanced digital mammography (CEDM) is comparable to breast MRI in evaluating residual breast cancer after neoadjuvant endocrine therapy or chemotherapy. CEDM may be a more accessible and cost-effective alternative to breast MRI, with fewer anxiety-provoking effects for patients.
Large racial disparities were found in the survival of patients with ovarian, colon, and breast cancers in the United States. Black women had consistently worse survival compared to white women, despite similar stage distributions. The five-year net survival for black women was lower than for white women in all three types of cancer.
Research suggests breast cancer screening in the Netherlands has a marginal effect on mortality, with improved treatments associated with a 28% reduction. Overdiagnosis has steadily increased due to extended screening and digital mammography.
A recent study by the University of Kent has identified Myosin VI as a key protein involved in the production of specific genes linked to breast cancer cell growth. This discovery may lead to new diagnostic clues and therapeutic targets for patients with oestrogen-sensitive breast cancer.
A national survey of physicians found that those with a social network member with poor breast cancer prognosis are more likely to recommend routine mammograms for younger and older patients. This suggests the need for better understanding the personal experiences that shape clinicians' practices.
Researchers from the University of Copenhagen developed a new vaccine technique that can fight HER2-positive breast cancer in mice with a 50-100% prevention rate. The vaccine works by inducing large amounts of antibodies targeted at cancer cells, preventing tumors from developing and slowing down cancer progression.
Researchers identify barriers to applying international guidelines, citing unique challenges such as younger age at presentation and lack of national breast screening programmes. The need for specific regional guidelines was agreed upon by 90.6% of survey responders.
A new study suggests that an American Cancer Society program has been effective in promoting improvements in colorectal cancer screening rates in federally qualified health centers. Funded FQHCs increased their CRC screening rates significantly more than nonfunded FQHCs, with increases of 8.7% and 12.7% over three years.
The study found that urban American-Indian and Alaskan Native individuals had a higher risk of mortality from prostate and breast cancer, with AIANs facing an 87% increased risk for prostate cancer-specific mortality. The community's unique history of social and environmental injustices may be contributing to these disparities.
Researchers will evaluate a promising experimental assay and novel research into microRNAs to predict breast cancer risk. The study aims to develop personalized treatment and improve outcomes for tens of thousands of women annually.
Researchers found that abbreviated breast MRI (AB-MR) detected five additional cancers in asymptomatic women with dense breast tissue after a negative mammogram. AB-MR may be a better option than whole breast ultrasound for supplemental screening.
A new study published in The Lancet Diabetes & Endocrinology found that diabetes and being overweight or obese are responsible for nearly 800,000 new cancer cases globally. High BMI was linked to twice as many cancers as diabetes, with liver cancer and endometrial cancer being the most common types.
A new study analyzed breast cancer tumor samples over time, revealing common characteristics among treatment-resistant tumors. The research aims to understand tumor changes in real-time to adjust treatment accordingly.
A new American Cancer Society study calculates the contribution of several modifiable risk factors to cancer occurrence. The study found that more than 42% of all cancer cases and deaths in the US are associated with these major modifiable risk factors, many of which can be mitigated with prevention strategies.
A joint effort by breast cancer researchers and bioinformaticians has provided new insights into breast development, revealing previously unrecognized cell types. The study used single-cell RNA-sequencing to identify a dramatic shift in gene expression around puberty.
A new study by Einstein Medical Center found that 71% of women surveyed preferred annual mammograms, citing empowerment and education as key factors. The research challenges the USPSTF's biennial screening recommendation, highlighting the importance of women's preferences in healthcare decisions.
A new study suggests that overweight women with higher body mass index (BMI) may need shorter intervals between mammography screening exams. Women with higher BMI face an increased risk of not detecting their breast tumor until it has become large, leading to a worse prognosis.